Ikarian Capital’s Cidara Therapeutics CDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-300,000
Closed -$66.3M 173
2025
Q4
$66.3M Buy
+300,000
New +$48.5M 5.17% 2
2025
Q3
Sell
-501,600
Closed -$24.4M 176
2025
Q2
$24.4M Buy
+501,600
New +$12.1M 4.69% 1

Ikarian Capital's CDTX Position: Q1 2026 in Review

Ikarian Capital sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 273,243 shares — an estimated $60.4M sold.

Ikarian Capital first reported a position in CDTX in Q4 2024 and held it in 5 quarters. The position peaked at $60.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

  • Ikarian Capital reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 273,243 Cidara Therapeutics shares in Q1 2026, an estimated $60.4M.
  • Ikarian Capital first reported a position in Cidara Therapeutics in Q4 2024 and held it in 5 quarters.
  • Ikarian Capital's Cidara Therapeutics position peaked at $60.4M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.